436 related articles for article (PubMed ID: 36769165)
21. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
22. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
23. Current treatment of non-alcoholic fatty liver disease.
Paternostro R; Trauner M
J Intern Med; 2022 Aug; 292(2):190-204. PubMed ID: 35796150
[TBL] [Abstract][Full Text] [Related]
24. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
26. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
[TBL] [Abstract][Full Text] [Related]
27. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
29. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
30. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
31. The diagnosis and treatment of non-alcoholic fatty liver disease.
Altinbas A; Sowa JP; Hasenberg T; Canbay A
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
Kechagias S; Ekstedt M; Simonsson C; Nasr P
Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
[TBL] [Abstract][Full Text] [Related]
33. Liver transplantation and non-alcoholic fatty liver disease.
Zezos P; Renner EL
World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
[TBL] [Abstract][Full Text] [Related]
34. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
Hardy T; Wonders K; Younes R; Aithal GP; Aller R; Allison M; Bedossa P; Betsou F; Boursier J; Brosnan MJ; Burt A; Cobbold J; Cortez-Pinto H; Day CP; Dufour JF; Ekstedt M; Francque S; Harrison S; Miele L; Nasr P; Papatheodoridis G; Petta S; Tiniakos D; Torstenson R; Valenti L; Holleboom AG; Yki-Jarvinen H; Geier A; Romero-Gomez M; Ratziu V; Bugianesi E; Schattenberg JM; Anstee QM;
Contemp Clin Trials; 2020 Nov; 98():106175. PubMed ID: 33045403
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
Arshad T; Golabi P; Henry L; Younossi ZM
Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
[TBL] [Abstract][Full Text] [Related]
36. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
37. NAFLD: Mechanisms, Treatments, and Biomarkers.
Nassir F
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740949
[TBL] [Abstract][Full Text] [Related]
38. Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma.
Rana M; Saini M; Das R; Gupta S; Joshi T; Mehta DK
Microrna; 2023; 12(2):99-113. PubMed ID: 37005546
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
40. Fatty Liver Disease: Diagnosis and Stratification.
Saiman Y; Duarte-Rojo A; Rinella ME
Annu Rev Med; 2022 Jan; 73():529-544. PubMed ID: 34809436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
